TIDMPRTC
PureTech Health PLC
08 February 2021
8 February 2021
PureTech Health plc
PureTech Founded Entity Vedanta Biosciences Appoints Mark
Mullikin as Chief Financial Officer
Extensive biotech finance and investor relations expertise
includes leadership roles at Editas Medicine and Novartis
PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company dedicated to
discovering, developing and commercializing highly differentiated
medicines for devastating diseases , is pleased to note that its
Founded Entity, Vedanta Biosciences, today announced the
appointment of Mark Mullikin as Chief Financial Officer. Mr.
Mullikin brings 25 years of experience raising and deploying
capital for life sciences companies, and most recently held
leadership roles in finance and investor relations at
publicly-traded Editas Medicine and Novartis.
Mr. Mullikin joins Vedanta from Editas Medicine, where he served
as Vice President, Finance and Investor Relations and was involved
in raising $700 million of equity capital. Prior to this role, Mr.
Mullikin worked for Novartis in roles focused on financial and
strategic planning in addition to health economics and pricing.
Before joining Novartis, he was a healthcare equity analyst at
Adage Capital Management and Piper Sandler and began his career in
the finance and strategy practice at Deloitte Consulting.
The full text of the announcement from Vedanta is as
follows:
Vedanta Biosciences Appoints Mark Mullikin as Chief Financial
Officer
Extensive biotech finance and investor relations expertise
includes leadership roles at Editas Medicine and Novartis
CAMBRIDGE, February 8, 2021 - Vedanta Biosciences , a leading
clinical-stage company developing a new category of therapies for
immune-mediated diseases based on rationally defined consortia of
human microbiome-derived bacteria, today announced the appointment
of Mark Mullikin as Chief Financial Officer. Mr. Mullikin brings 25
years of experience raising and deploying capital for life sciences
companies, and most recently held leadership roles in finance and
investor relations at publicly-traded Editas Medicine and
Novartis.
"Mark's experience overseeing the finances of a public biotech
and previously as a healthcare equity analyst, provide him a unique
and broad perspective of the biotech field," said Bernat Olle,
Ph.D., Co-Founder and Chief Executive Officer of Vedanta
Biosciences. "We are excited to welcome Mark to the Vedanta team
and look forward to his contributions."
Mr. Mullikin joins Vedanta from Editas Medicine, where he served
as Vice President, Finance and Investor Relations and was involved
in raising $700 million of equity capital. Prior to this role, Mr.
Mullikin worked for Novartis in roles focused on financial and
strategic planning in addition to health economics and pricing.
Before joining Novartis, he was a healthcare equity analyst at
Adage Capital Management and Piper Sandler and began his career in
the finance and strategy practice at Deloitte Consulting. Mr.
Mullikin earned his M.B.A. in finance from the MIT Sloan School of
Management and his B.A. in economics from the University of
Chicago.
"Vedanta has established a leadership position in the microbiome
field pioneering defined bacterial consortia as a new class of
therapeutics," said Mr. Mullikin. "I am thrilled to join at this
pivotal moment of growth with key clinical trial readouts
anticipated this year."
About Vedanta Biosciences
Vedanta Biosciences is leading the development of a potential
new category of oral therapies based on rationally defined
consortia of bacteria derived from the human microbiome. The
company's clinical-stage pipeline includes product candidates being
evaluated for the treatment of high-risk C. difficile infection,
inflammatory bowel diseases, advanced or metastatic cancers, and
food allergy. These investigational therapies are grounded in
pioneering research - published in leading journals including
Science , Nature , and Cell - to identify beneficial bacteria that
live symbiotically within the healthy human gut, fight pathogens
and induce a range of potent immune responses. Vedanta Biosciences
controls a foundational portfolio of more than 40 patents and has
built what is believed to be the world's biggest library of
bacteria derived from the human microbiome. Proprietary
capabilities include deep expertise in consortium design, vast
datasets from human interventional studies and cGMP-compliant
manufacturing of oral live biotherapeutics containing pure,
clonally derived bacterial consortia in powdered form. Vedanta
Biosciences was founded by PureTech Health (LSE: PRTC, Nasdaq: PRTC
) and a global team of scientific co-founders who pioneered
Vedanta's modern understanding of the cross-talk between the
microbiome and the immune system.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases,
central nervous system disorders and inflammatory and immunological
diseases, among others. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech's Founded Entities,
as of the date of PureTech's most recently filed Registration
Statement on Form 20-F, was comprised of 24 products and product
candidates, including two that have received FDA clearance and
European marketing authorization. All of the underlying programs
and platforms that resulted in this pipeline of product candidates
were initially identified or discovered and then advanced by the
PureTech team through key validation points based on the Company's
unique insights into the biology of the brain, immune and gut, or
BIG, systems and the interface between those systems, referred to
as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, our expectations regarding the potential therapeutic benefits
of our product candidates, our expectations regarding the
appointment of Mark Mullikin as Chief Financial Officer and those
risks and uncertainties described in the risk factors included in
the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media
Allison Mead Talbot Ben Atwell, Rob Winder
+1 617 651 3156 +44 (0) 20 3727 1000
amt@puretechhealth.com ben.atwell@FTIconsulting.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUPUACPUPGPPA
(END) Dow Jones Newswires
February 08, 2021 07:00 ET (12:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024